Abstract
BACKGROUND:
The herpes zoster vaccine is effective in preventing herpes zoster and postherpetic neuralgia in immunocompetent older adults. However, its safety has not been described in depth.
OBJECTIVE:
To describe local adverse effects and short- and long-term safety profiles of herpes zoster vaccine in immunocompetent older adults.
DESIGN:
Randomized, placebo-controlled trial with enrollment from November 1998 to September 2001 and follow-up through April 2004 (mean, 3.4 years). A Veterans Affairs Coordinating Center generated the permutated block randomization scheme, which was stratified by site and age. Participants and follow-up study personnel were blinded to treatment assignments. (ClinicalTrials.gov registration number: NCT00007501)
SETTING:
22 U.S. academic centers.
PARTICIPANTS:
38 546 immunocompetent adults 60 years or older, including 6616 who participated in an adverse events substudy.
INTERVENTION:
Single dose of herpes zoster vaccine or placebo.
MEASUREMENTS:
Serious adverse events and rashes in all participants and inoculation-site events in substudy participants during the first 42 days after inoculation. Thereafter, vaccination-related serious adverse events and deaths were monitored in all participants, and hospitalizations were monitored in substudy participants.
RESULTS:
After inoculation, 255 (1.4%) vaccine recipients and 254 (1.4%) placebo recipients reported serious adverse events. Local inoculation-site side effects were reported by 1604 (48%) vaccine recipients and 539 (16%) placebo recipients in the substudy. A total of 977 (56.6%) of the vaccine recipients reporting local side effects were aged 60 to 69 years, and 627 (39.2%) were older than 70 years. After inoculation, herpes zoster occurred in 7 vaccine recipients versus 24 placebo recipients. Long-term follow-up (mean, 3.39 years) showed that rates of hospitalization or death did not differ between vaccine and placebo recipients.
LIMITATIONS:
Participants in the substudy were not randomly selected. Confirmation of reported serious adverse events with medical record data was not always obtained.
CONCLUSION:
Herpes zoster vaccine is well tolerated in older, immunocompetent adults.
PRIMARY FUNDING SOURCE:
Cooperative Studies Program, Department of Veterans Affairs, Office of Research and Development; grants from Merck to the Veterans Affairs Cooperative Studies Program; and the James R. and Jesse V. Scott Fund for Shingles Research.